Abstract
Immunotherapy with monoclonal antibodies passes through the golden age in the field of antitumoral therapy. This kind of therapy achieves significant and long‑lasting treatment responses and reveals prolongation of progression free survival, overall survival together with quality‑of‑life improvement.
Cemiplimab is a fully human monoclonal antibody which is currently reimbursed in the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation. The article discusses the cemiplimab drug profile, focused on its limitation of use, therapeutic effect and adverse events.
